

SYSTEMIC IMMUNOMODULATORY THERAPY IN THE MANAGEMENT OF ATOPIC DERMATITIS: THE VALUE OF TRALOKINUMAB

TERAPIA INMUNOMODULADORA SISTÉMICA EN EL TRATAMIENTO DE LA DERMATITIS ATÓPICA:
EL VALOR DE TRALOKINUMAB

Sara Muñoz Ordóñez  ^{1,a}, Jessika Alexandra Layos  ^{2,a}, María Paula García Lozano  ^{3,a},
Yelson Alejandro Picón Jaimes  ^{4,a,b,c}

Mr. Editor:

Atopic dermatitis is a chronic inflammatory skin disease that substantially impacts the quality of life and functional capacity of those who suffer from it ^(1,2). In the midst of describing the pathogenesis and pathophysiology of this condition, the aberrant activity of interleukins (ILs) stands out, mainly IL-13 type 2. Currently, there is no definitive and safe treatment to address this disease ⁽²⁾. Traditionally, antibiotic therapy and corticosteroids have been indicated, but given the adverse effects commonly reported with these drugs, it is not reproducible or safe to continue with these regimens ⁽³⁾. Over the last few years, some agents with immunomodulatory potential have been proposed, which could change the course of atopic dermatitis. Within the global health objectives stipulated for the year 2030, there is the need to develop drugs that allow control of the burden of diseases that generate pathological entities that considerably affect both the quality of life and the catastrophic expense of the global population, with main emphasis on low- and middle-income countries, where difficulties prevail for timely and effective access to health services and targeted treatments ⁽⁴⁾. Therefore, the effort to find an agent that regulates chronicity or solves this disease is a priority both for dermatology and for global health.

Tralokinumab is a complete IgG4 monoclonal antibody targeting IL-13 whose pharmacokinetics, effectiveness, efficacy, and safety are still being studied. Compared to other therapies, some studies such as Drucker et al. ⁽³⁾, where they recently systematized evidence on systemic immunomodulatory treatments, including 60 clinical trials with a total of 16,579 patients. Among the drugs studied are Abrocitinib (Janus kinase [JAK] inhibitor), Upadacitinib (selective and reversible JAK inhibitor), Baricitinib (JAK1 and JAK2 inhibitor), Dupilumab (IL-4 inhibitor and IL-13) and Tralokinumab. The authors showed that, at 16 weeks of treatment, Abrocitinib (200 mg daily doses) and Upadacitinib (30 mg daily doses) reduced the Eczema Area and Severity Index (EASI) to a greater extent, compared to Dupilumab (at doses of 600 and 300 mg every two weeks). Likewise, Abrocitinib (in daily doses of 100 mg), Baricitinib (in daily doses of 2 and 4 mg) and Tralokinumab (in doses of 600 and 300 mg every two weeks), slightly decreased the EASI, compared to Dupilumab, which had better performance ⁽³⁾.

These results were similar for the other indices also evaluated, Patient Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), y Peak Pruritus Numeric Rating Scales (PP-NRS). This allowed us to conclude that Abrocitinib and Upadacitinib are the most effective agents in controlling atopic dermatitis ⁽³⁾.

¹ Departamento de Investigaciones, Fundación para la Investigación en Dermatología (FUNINDERMA), Bogotá, Colombia.

² Facultad de Medicina, Universidad Autónoma de Bucaramanga, Bucaramanga, Colombia.

³ Facultad de Medicina, Universidad del Rosario, Bogotá, Colombia.

⁴ Fac Ciències Salut Blanquerna, Univ Ramon Llull, Barcelona, España

^a Physician

^b Master in Epidemiology and Public Health

^c PhD Student in Health, Welfare and Bioethics

Cite as: Muñoz Ordóñez S, Layos JA, García Lozano MP, Picón Jaimes YA. Systemic immunomodulatory therapy in the management of atopic dermatitis: the value of Tralokinumab. Rev Fac Med Hum. 2023;23(2):176-178. [doi:10.25176/RFMH.v23i3.5593](https://doi.org/10.25176/RFMH.v23i3.5593)

Journal home page: <http://revistas.urp.edu.pe/index.php/RFMH>

Article published by the Magazine of the Faculty of Human Medicine of the Ricardo Palma University. It is an open access article, distributed under the terms of the Creative Commons License: Creative Commons Attribution 4.0 International, CC BY 4.0 (<https://creativecommons.org/licenses/by/4.0/>), that allows non-commercial use, distribution and reproduction in any medium, provided that the original work is duly cited. For commercial use, please contact revista.medicina@urp.pe



Nevertheless, it is necessary to highlight that the studies that included Tralokinumab were particularly trials up to phase II, of which many results were not clearly known. At the beginning of 2021, the results of the ECZTRA 3 study (double-blind randomized controlled trial) were published, which evaluated Tralokinumab (300 mg dose every two weeks or four weeks) plus topical corticosteroids in the management of moderate to severe atopic dermatitis, in 369, distributed at a ratio of 2:1 in favor of the intervention group⁽⁵⁾. As primary outcomes, an Investigator's Global Assessment (IGA) score of 0/1 and 75% EASI improvement (EASI 75) were determined. It was evidenced that at week 16, the intervention group had a higher proportion of patients who achieved IGA 1/0 (38.9% vs. 26.2%, p= 0.015) and EASI 75 (56.0% vs. 35.7%, P <0.001). These results were similar with the two and four week doses (with evaluation at week 32), and the incidence of adverse events was similar in both groups. This allowed us to conclude that Tralokinumab was effective and well-tolerated in the management of moderate-severe atopic dermatitis⁽⁵⁾.

In March 2022, the results of the ECZTRA 7 study were published⁽⁶⁾, with a design similar to the ECZTRA 3 study, which evaluated Tralokinumab plus topical corticosteroids in moderate to severe dermatitis with inadequate response or intolerance to cyclosporine A. Two hundred seventy-seven individuals were randomized 1:1; The intervention group was administered Tralokinumab at a dose of 300 mg every two weeks plus topical corticosteroid as needed. To evaluate the outcome, the improvement of the EASI 75 was analyzed. It was observed that at week 16, the intervention group obtained a significant improvement in the EASI 75 in a superior way, compared to the control group (64.2% vs. 50.5%, p= 0.018), whose effect persisted until week 26⁽⁶⁾. This effect was more significant in those with prior therapeutic failure compared to placebo plus corticosteroid (57% vs. 41%). As in the ECZTRA 3 study, the incidence of adverse events was similar in both groups. This allowed us to conclude that Tralokinumab is effective and safe in the management of

uncontrolled atopic dermatitis or with a contraindication to cyclosporine A⁽⁶⁾. Compared to other immunomodulatory therapies, Tralokinumab does not have black box warnings, and its mechanism of action is directly involved with immunological lines associated with the most up-to-date pathogenesis described⁽²⁾. Compared to other therapies, an advantage is the dosage of Tralokinumab in a wide time window (every 2 or 4 weeks), which may favor treatment adherence. Within the studies on this agent, specifically on its pharmacokinetics, it is still debated whether the distribution is really affected in overweight or obese patients, but it seems that this factor is not significant⁽⁷⁾. Among the adverse events to consider, which have been reported in the literature, are, for example, the one reported by Lai et al.⁽⁸⁾, on vernal keratoconjunctivitis; although the published case reports are counted.

To date, studies that are elucidating and expanding the therapeutic potential of Tralokinumab continue appearing^(1,9). However, the results of the trials show that it is a good therapeutic option that needs to be studied in greater depth in more populations with different epigenetic characteristics that could influence performance⁽¹⁰⁾. This goes added to the statement made by Adikusuma et al.⁽¹¹⁾ regarding the need to promote genetic networks and genomic information in regions where there are no massive databases that allow the extrapolation capacity to be analyzed and integrated with greater complexity of this drug. Unfortunately, in Latin America and the Caribbean, very few centers or researchers have studied this condition or contributed to the development of international multicenter studies, to favor the production of knowledge about the behavior and management of diseases with a low research rate^(10,11). It is necessary to keep abreast of studies that perform subgroup analyzes that determine what other factors may influence the efficiency, efficacy, and safety of Tralokinumab. Meanwhile, the value of Tralokinumab in the approach to this disease and its potential use in healthcare practice must be recognized.

Authorship contributions: All the authors participated in the research through the elaboration of the project, collection and analysis of the information, as well as in the preparation of the manuscript of the present investigation.

Financing: Self-financed.

Conflicts of interest: None of the authors has a conflict of interest, in accordance with their declaration.

Received: March 31, 2023.

Approved: April 14, 2023.

Correspondence: Yelson Alejandro Picón Jaimes.

Address: Fac Ciències Salut Blanquerna, Univ Ramon Llull, Barcelona, España.
E-mail: colmedsurg.center@gmail.com





REFERENCES

1. Kelly KA, Perche PO, Feldman SR. Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data. *Clin Cosmet Investig Dermatol.* 2022; 15:1037-1043. DOI: [10.2147/CCID.S267217](https://doi.org/10.2147/CCID.S267217)
2. Singh R, Taylor A, Shah MA, Strowd LC, Feldman SR. Review of Tralokinumab in the Treatment of Atopic Dermatitis. *Ann Pharmacother.* 2023; 57(3):333-340. DOI: [10.1177/10600280221105686](https://doi.org/10.1177/10600280221105686)
3. Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochwerg B, et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis. *JAMA Dermatol.* 2022; 158(5):523-532. DOI: [10.1001/jamadermatol.2022.0455](https://doi.org/10.1001/jamadermatol.2022.0455)
4. Institute of Medicine (US) Committee on the US Commitment to Global Health. The US Commitment to Global Health: Recommendations for the Public and Private Sectors. Washington (DC): National Academies Press (US); 2009. Summary. Disponible en: <https://www.ncbi.nlm.nih.gov/books/NBK23788/>
5. Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. *Br J Dermatol.* 2021; 184(3):450-463. DOI: [10.1111/bjd.19573](https://doi.org/10.1111/bjd.19573)
6. Gutermuth J, Pink AE, Worm M, Soldbro L, Bjerregård Øland C, Weidinger S. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of cyclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). *Br J Dermatol.* 2022; 186(3):440-452. DOI: [10.1111/bjd.20832](https://doi.org/10.1111/bjd.20832)
7. Soehoel A, Larsen MS, Timmermann S. Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis. *Clin Pharmacol Drug Dev.* 2022; 11(8):910-921. DOI: [10.1002/cpdd.1113](https://doi.org/10.1002/cpdd.1113)
8. Lai B, Phan K, Lewis N, Shumack S. A rare case of vernal keratoconjunctivitis in a patient with atop dermatitis treated with tralokinumab. *J Eur Acad Dermatol Venereol.* 2022; 36(5):e343-e345. DOI: [10.1111/jdv.17824](https://doi.org/10.1111/jdv.17824)
9. Wang B, Goodman J, Roskos LK. Mechanistic modeling of a human IgG4 monoclonal antibody (tralokinumab) Fab-arm exchange with endogenous IgG4 in healthy volunteers. *CPT Pharmacometrics Syst Pharmacol.* 2022; 11(4):438-446. DOI: [10.1002/psp4.12738](https://doi.org/10.1002/psp4.12738)
10. Lozada-Martinez ID, Suarez-Causado A, Solana-Tinoco JB. Ethnicity, genetic variants, risk factors and cholelithiasis: The need for eco-epidemiological studies and genomic analysis in Latin American surgery. *Int J Surg.* 2022; 99:106589. DOI: [10.1016/j.ijsu.2022.106589](https://doi.org/10.1016/j.ijsu.2022.106589).
11. Adikusuma W, Irham LM, Chou WH, Wong HS, Mugiyanto E, Ting J, et al. Drug Repurposing for Atopic Dermatitis by Integration of Gene Networking and Genomic Information. *Front Immunol.* 2021; 12:724277. DOI: [10.3389/fimmu.2021.724277](https://doi.org/10.3389/fimmu.2021.724277).
12. Pérez-Fontalvo NM, De Arco-Aragón MA, Jimenez-García JDC, Lozada-Martinez ID. Molecular and computational research in low- and middle-income countries: Development is close at hand. *J Taibah Univ Med Sci.* 2021; 16(6):948-949. DOI: [10.1016/j.jtumed.2021.06.010](https://doi.org/10.1016/j.jtumed.2021.06.010).

